Welcome to our dedicated page for Novanta news (Ticker: NOVT), a resource for investors and traders seeking the latest updates and insights on Novanta stock.
Novanta Inc. (Nasdaq: NOVT) is a global supplier of core technology solutions for medical, life science, and advanced industrial original equipment manufacturers. As a trusted technology partner to medical and advanced technology equipment manufacturers, the company frequently features in news related to its financial performance, capital markets activity, and participation in investor and industry conferences.
News about Novanta often includes quarterly earnings releases and related conference call announcements, where the company reports GAAP results alongside non-GAAP metrics such as Adjusted EBITDA, Adjusted Diluted EPS, and Organic Revenue Growth. These updates provide insight into how its precision medicine, precision manufacturing, medical solutions, robotics and automation, and advanced surgery businesses are performing.
Investors can also expect coverage of capital structure developments, such as the offering and pricing of tangible equity units that combine prepaid stock purchase contracts with senior amortizing notes, as well as amendments to credit agreements and details of senior credit facilities. Announcements about share repurchase authorizations by the Board of Directors are another recurring news theme, reflecting decisions on capital allocation.
In addition, Novanta regularly appears in conference and investor event schedules, including healthcare and industrial conferences hosted by firms such as J.P. Morgan, Baird, Jefferies, and CJS Securities. These events highlight management’s engagement with the investment community and provide forums for discussing strategy and market positioning.
This news page aggregates such items in one place, helping readers follow Novanta’s earnings announcements, financing activities, share repurchase plans, and public presentations over time.
Novanta Inc. (NOVT), a trusted technology partner for medical and advanced technology equipment makers, has announced its participation in Baird's 2024 Global Healthcare Conference. The event is set to take place on Tuesday, September 10, 2024, in New York, NY.
Matthijs Glastra, the Chair & Chief Executive Officer of Novanta, is scheduled to present at the conference. This presentation offers an opportunity for investors and industry professionals to gain insights into Novanta's strategies, innovations, and market position within the healthcare technology sector.
Baird's Global Healthcare Conference is a significant event that brings together companies, investors, and experts in the healthcare industry. Novanta's participation underscores its commitment to engaging with the investment community and showcasing its role in advancing medical and advanced technology equipment manufacturing.
Novanta, a key technology partner for medical and advanced equipment manufacturers, will release its Q2 2024 financial results on August 6, 2024. A conference call to discuss these results will be held at 10:00 a.m. ET the same day. Participants can join the call by dialing (888) 346-3959 or via a live webcast on the Events & Presentations page of Novanta's website. A replay of the webcast will be accessible for nearly two months until September 30, 2024. Investors can visit the company's website for more details.
Novanta (Nasdaq: NOVT), a key technology partner for medical and advanced technology equipment manufacturers, announced that its Chief Financial Officer, Robert Buckley, will be presenting at the CJS Securities 24th Annual New Ideas Summer Conference.
The event is scheduled for Wednesday, July 10, 2024, in White Plains, New York.
This presentation is expected to highlight Novanta's latest innovations and strategic outlook, providing insights into the company's future growth and investment potential.
Novanta Inc. (Nasdaq: NOVT) reported strong financial results for the first quarter of 2024 with GAAP revenue of $231 million, net income of $15 million, and diluted earnings per share of $0.41. The company achieved adjusted earnings per share of $0.74 and adjusted EBITDA of $50 million. Novanta showed a 5.4% increase in GAAP revenue compared to the first quarter of 2023, with organic revenue growth decreasing by 4.2%. Operating cash flow for the quarter more than doubled year over year. The company expects GAAP revenue of $230 million to $235 million for the second quarter of 2024.
Novanta Inc. (Nasdaq: NOVT) will be represented by CFO Robert Buckley at Baird's 2024 Global Consumer, Technology & Services Conference on June 5, 2024, in New York. Novanta is a technology partner serving medical and advanced technology equipment manufacturers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.